BioSpace News Archive

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week. The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the curr

Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis

Magenta Therapeutics Provides Portfolio Update : Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones — MGTA-145 first-line mobilization program to move into Phase 2 studies in autologous and allogeneic patients in 2020, including allogeneic study in newly announced collaboration with National Marrow Donor Program® (NMDP)/Be The Match® — — MGTA-117 antibody-drug conjugate (ADC)-based conditioning progr

Project Will Evolve Data Sharing Paradigm with the Goal of Rapidly Bringing Data from ongoing Clinical Trials to the Research Community

Partner Therapeutics, a commercial biotechnology company, announces the enrollment of the first patient dosed in a Phase II investigator-initiated study evaluating the efficacy and safety of Leukine ® (sargramostim, rhu-GM-CSF) in T cell replete HLA-mismatched haploidentical stem cell transplant recipients who are receiving post-

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) (Germany: TQB2) subsidiary U-Protein Express BV (“UPE”) today announced the availability of its new recombinant SARS-CoV-2 proteins, and other proteins associated with COVID-19,

With the support of Zymo Research products, two California-based companies, Fulgent Genetics located in Temple City and Curative Inc. based in Menlo Park, have received Emergency Use Authorizations from the US Food and Drug Administration for their rRT-PCR tests for the detection of SARS-CoV-2 in specimens collected from individuals.

Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific / 4:30 p.m. Eastern that same day. A question and answer session will follow management’s remarks. The conf

SkinScience Labs, Creator of Award-Winning Dr. Denese Skin Care & Anti-Aging Product Lines, Enters Hand Sanitizer Market with Proprietary Formula Developed by Founder Adrienne Denese, MD., Ph.D.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows: JMP Securities Hematology and Oncology Forum Date: Thursday, June 18 Presentation Time: 4:00 p.m. ET A live webcast o